TY - JOUR
T1 - Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias
AU - Moretta, L.
AU - Locatelli, Franco
AU - Pende, D.
AU - Mingari, M. C.
AU - Moretta, A.
PY - 2010
Y1 - 2010
N2 - Natural killer (NK) cells, a major cell type of the innate immunity, express surface receptors that regulate potent effector functions such as cytolytic activity and release of cytokines playing a central role in inflammatory response and immunoregulation. In this contribution, we briefly outline the major steps from the discovery of human leukocyte antigen (HLA)-class I-specific inhibitory receptors in humans to recent successful clinical applications in the cure of high-risk leukemias both in adults and in pediatric patients. A central role is played by 'alloreactive' NK cells originated from donor's CD 34+ cells in eradicating leukemic cells in the setting of T-cell-depleted haploidentical hemopoietic stem cell transplantation. Because alloreactive NK cells play a central role also in preventing graft rejection and graft- vs-host disease, they may represent an ideal tool to treat patients affected by acute high-risk leukemias.
AB - Natural killer (NK) cells, a major cell type of the innate immunity, express surface receptors that regulate potent effector functions such as cytolytic activity and release of cytokines playing a central role in inflammatory response and immunoregulation. In this contribution, we briefly outline the major steps from the discovery of human leukocyte antigen (HLA)-class I-specific inhibitory receptors in humans to recent successful clinical applications in the cure of high-risk leukemias both in adults and in pediatric patients. A central role is played by 'alloreactive' NK cells originated from donor's CD 34+ cells in eradicating leukemic cells in the setting of T-cell-depleted haploidentical hemopoietic stem cell transplantation. Because alloreactive NK cells play a central role also in preventing graft rejection and graft- vs-host disease, they may represent an ideal tool to treat patients affected by acute high-risk leukemias.
KW - activating receptors
KW - acute lymphoblastic leukemias
KW - acute myeloid leukemias
KW - natural killer cells
KW - killer immunoglobulin-like receptors
KW - killer immunoglobulin-like repertoire
KW - hemopoietic stem cell transplantation
KW - activating receptors
KW - acute lymphoblastic leukemias
KW - acute myeloid leukemias
KW - natural killer cells
KW - killer immunoglobulin-like receptors
KW - killer immunoglobulin-like repertoire
KW - hemopoietic stem cell transplantation
UR - http://hdl.handle.net/10807/252394
U2 - 10.1111/j.1399-0039.2009.01404.x
DO - 10.1111/j.1399-0039.2009.01404.x
M3 - Article
SN - 0001-2815
VL - 75
SP - 103
EP - 109
JO - Tissue Antigens
JF - Tissue Antigens
ER -